Respiratory Inhaler Devices Market

Respiratory Inhaler Devices Market: Increasing Prevalence of Asthma and COPD to drive the Global market for Respiratory Inhalers Devices; Global Industry Analysis and Opportunity Assessment, 2015 - 2025

Respiratory devices are medical devices are used to assist a patient encountering breathing problems resulting from respiratory disorders such as fibrosis, asthma, COPD and ARDS and others. On the basis of product type, the market has been segmented into dry powder inhaler (DPI), metered dose inhaler (MDI) and nebuliser. Nebuliser is further sub-segmented into compressed air nebuliser, ultrasonic nebuliser and mesh nebuliser.

Market Value and Forecast

In terms of value, the global respiratory inhaler devices market is estimated to expand at a CAGR of 4.3% during the forecast period. The global respiratory inhaler devices market value is expected to increase to US$ 43,214.0 Mn by 2025 end.

Market Dynamics

Growth of the global respiratory inhaler devices market is mainly driven by rising prevalence of asthma, chronic respiratory diseases, COPD and other respiratory diseases. However, lack of a single effective inhaler devices for all type of disease indication, side effects and complications during drug inhalation, lack of skilled pulmonologist, physicians and nurses, lack of awareness, coupled with high prices of inhaler devices are factors restraining market growth.

Patients are shifting towards combined therapies due to associated benefits such as more reliable in complex patients, increased efficacy and easy reimbursement policies associated with therapy. Combination therapies cost more compared to conventional therapies for patients with complex indications of respiratory disease. Increase in usage of combination therapies such as triple combination therapy for COPD patients is expected to drive growth of the global respiratory inhaler devices market over the forecast period.

Market Segmentation By Product

On the basis of product type, the market has been segmented into dry powder inhaler, metered dose inhaler and nebuliser. In terms of value, the metered dose inhaler segment is estimated to account for over 69.9% share of the global respiratory inhaler devices market by 2015 end, and is expected to remain dominant during the forecast period.

Global Respiratory Inhaler Devices Market Value

Market Segmentation By Disease Indication

On the basis of disease indication, the market has been segmented into asthma, COPD, pulmonary arterial hypertension and other respiratory diseases. COPD is expected to be third leading cause of death and fifth leading cause of disability by 2020 end. Numerous health awareness programmes being conducted across the globe are expected to result in the COPD segment registering a higher CAGR of 4.8% over the forecast period.

Market Segmentation By Technology

On the basis of the technology, market has been segmented into manually operated inhaler devices and digitally operated inhaler devices. Digitally operated inhaler devices is expected to register a CAGR of 3.8% over the forecast period. Application of GPS and Bluetooth technology in inhaler devices is expected to drive demand for digitally operated inhaler devices over the forecast period.

Key Regions

The global respiratory inhaler devices market has been segmented into seven major regions namely North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan (APEJ), Japan, and Middle East & Africa. In terms of value, North America is estimated to dominate the market with 40.0% share of the overall respiratory inhaler devices market by 2015 end. APEJ is estimated to be the fastest growing market, registering a CAGR of 5.0% in terms of value over the forecast period. Currently, metered dose inhaler is a major contributor in markets in Europe, North America and parts of Asia Pacific, while nebuliser segment is expected to exhibit a CAGR of 3.8% in terms of value during the forecast period.

Key Players

Some key players identified in the global respiratory inhaler devices market report include: AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd. These companies are focusing towards enhancing their product portfolio through the introduction of innovative and cost-effective products to strengthen position in the market in the long term.

Future Market Insights offers a 10-year forecast of the global respiratory inhaler devices market between 2015 and 2025. In terms of value, the market is expected to register a CAGR of 4.3% during the projected period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the respiratory inhaler devices market over the forecast period.

Report Description

This Future Market Insights report examines the respiratory inhaler devices market for the period 2015–2025. The primary objective of the report is to offer insights into developments in the respiratory inhaler devices market that are significantly transforming global businesses and enterprises. Increasing prevalence of asthma, COPD and other respiratory diseases coupled with rising awareness is predicted to increase usages of respiratory inhaler devices worldwide. This is expected to bolster growth of the respiratory inhaler devices market over the next five to six years. Increasing demand for inhalation respiratory inhaler devices for controlling asthma and other respiratory disease, especially among children and elderly population, is expected to drive growth of respiratory inhaler devices market during the forecast period. Companies are focusing on regions and sections where prevalence of asthma, and chronic lung disease are increasing such as Asia Pacific and MEA.

The respiratory inhaler devices market report begins with an overview of the respiratory inhaler devices market in terms of value. This section includes FMI analysis of key trends, drivers and restraints and opportunity, which are factors influencing growth of the respiratory inhaler devices market. Impact analysis of key growth drivers and restraints based on the weighted average model is included in the respiratory inhaler devices market report to better equip clients with crystal clear decision-making insights.

The global respiratory inhaler devices market is segmented on the basis of products type into dry powder inhaler (DPI), metered dose inhaler (MDI) and nebuliser. Nebuliser is further sub-segmented into compressed air nebuliser, ultrasonic nebuliser and mesh nebuliser. A detailed analysis has been provided for every segment and sub-segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

The next section of the report highlights respiratory inhaler devices adoption by region. It provides a market outlook for 2015–2025 and sets the forecast within the context of the respiratory inhaler devices market. The study discusses key regional trends contributing to growth of the respiratory inhaler devices market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa.

The above sections – by product type and region – evaluate the present scenario and growth prospects of the respiratory inhaler devices market for the period 2015 –2025. We have considered 2014 as the base year and provide data for the forecast period.

To ascertain respiratory inhaler devices market size, we have also considered revenue generated by manufacturers. The forecast presented here assesses the total revenue by value across the respiratory inhaler devices market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the respiratory inhaler devices market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse on the basis of key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the respiratory inhaler devices market.

The respiratory inhaler devices segments in terms of product and regions are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the respiratory inhaler devices market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the respiratory inhaler devices market.

To understand key growth segments in terms of growth and adoption for dry powder inhaler, metered dose inhaler and nebuliser across the globe in the near future, Future Market Insights developed the respiratory inhaler devices market ‘Attractiveness Index’. The resulting index should help providers identify real market opportunities.

In the final section of the report, respiratory inhaler devices ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the respiratory inhaler devices product portfolio and key differentiators. Key categories of providers covered in the report are respiratory inhaler devices manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the respiratory inhaler devices value chain and the potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in respiratory inhaler devices marketplace.

Detailed profiles of the providers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings and recent developments in the respiratory inhaler devices market. Key competitors covered in terms of manufacturers include AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

Key Segments Covered

  • Product Type
    • Dry Powder Inhaler
    • Metered Dose Inhaler
    • Nebulizer
      • Ultrasonic Nebulizer
      • Compressed Air Nebulizer
      • Mesh Nebulizer
  • By Disease Indication
    • Asthma
    • COPD
    • Pulmonary Arterial Hypertension
    • Others Respiratory Disease
  • By Technology
    • Manually Operated Inhaler Devices
    • Digitally Operated Inhaler Devices

Key Regions/Countries Covered

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
  • Western Europe
    • EU5
    • Nordics
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
    • Greater China
    • India
    • ASEAN
    • Australia and New Zealand
    • Rest of APEJ
  • Japan
  • Middle East & Africa
    • GCC
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Key Companies

  • AstraZeneca
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • OMRON Healthcare Europe B.V.
  • PARI Medical Holding
  • Teva Pharmaceutical Industries Ltd.